Genetic and pharmacological inhibition of Kcnn4/KCa3.1 prevents or regresses cysts ex vivo, delays polycystic kidney disease in vivo and suggests a clinical trial candidate. This evidence concerns the gene KCNN4 and polycystic kidney disease.